Takotsubo cardiomyopathy (TC) is a rare complication of electroconvulsive therapy (ECT), an effective and safe treatment for severe cases of depression and psychosis. There are reports on 16 patients who developed TC after ECT, and these were predominantly female patients treated with antidepressants for depressive disorder. We describe a case of a 40-year-old male patient, with a history of schizophrenia and heavy caffeine and nicotine use, treated for acute psychotic episode with haloperidol and clozapine. Propranolol was administered because of clozapine-induced tachycardia. After 8 weeks without therapeutic response, the patient was referred for standard ECT procedure, which included premedication and bifrontotemporal stimulation. Two hours later, the patient experienced gastric pain and had increased troponin and natriuretic peptide levels and ST-elevation. After inotrope and anticoagulant treatment and replacement of antipsychotics, the patient remained stable. Contrary to common opinion, previous adrenergic blockade in this patient did not prevent TC occurrence. TC pathophysiology remains unclear although it has been related to the burst of norepinephrine neurons. Psychosis has also been associated with catecholamine dysfunction, and excessive psychological stress with long-term norepinephrine dysfunction. Animal models have shown that ECT, clozapine, and nicotine and caffeine use could considerably increase catecholamine levels. Clinical understanding of rare cardiac ECT complications could improve early recognition of patients at risk for TC and ensure safe ECT protocols.
Takotsubo cardiomyopathy is a rare complication of electroconvulsive therapy (ECT), an effective and safe treatment for severe depression and psychosis (1). It has been suggested that catecholamines play a role in takotsubo cardiomyopathy development (2).

CASE REPORT

A 40-year-old white man, severely addicted to nicotine and caffeine, without alcohol misuse history, was admitted to our psychiatry department in December 2017 due to positive psychotic symptoms and was prescribed haloperidol (30 mg/d), promazine (300 mg/d), and diazepam (30 mg/d). He and his family members denied the history of medical conditions, and no medical data on his earlier treatment were found in our hospital’s archives. Three weeks later, because of treatment resistance, haloperidol and promazine were discontinued, and clozapine was augmented to a final dose of 350 mg a day. On the sixth day of clozapine therapy, the patient developed tachycardia and was given propranolol (40 mg/d) for cardioprotection. As psychosis did not improve by the end of the week 8, ECT was indicated.

Informed consent and ethical approval for ECT application were obtained from the University Hospital Centre Zagreb. The patient also signed informed consent for medical data publication. Somatic and psychiatric pre-evaluation revealed no contraindications for ECT. The blood pressure was 110/70 mm Hg, heart rate 92/min, axillary temperature 36.0°C, and electrocardiogram (ECG) showed a sinus rhythm with intermediate axis without any abnormalities. ECT was first applied at week 10. Diazepam was discontinued. Atropine, propofol, and succinylcholine were administered as standard premedication. The electrical dose was titrated to the patient’s seizure threshold at 0.5-millisecond pulse width, 20-Hz frequency, 5.6-second stimulus duration, and 900-mA current using Thymatron® System IV (Somatics LLC, Chatham, IL, USA), and bifrontotemporal stimulation was applied. Two hours after ECT, the patient complained of gastric pain. He was pale and tachypnoic, without a palpable radial pulse. Initial laboratory tests showed the troponin T level of 1956 ng/L (reference range <14 ng/L) and N-terminal pro-b-type natriuretic peptide (NT-proBNP) of 12,409 ng/L (reference range <300 ng/L). ECG showed marked ST-elevation, with Q waves and deep symmetrical T wave inversion in anterior leads, along with QTc interval prolongation (525 ms), indicating possible acute anterior wall myocardial infarction. However, the patient denied chest pain and complained of shortness of breath. The echocardiographic exam revealed severely reduced left ventricle ejection fraction (15%), with only lateral wall contracting and a consequent apical thrombus. The patient was immediately transferred to the Coronary Care Unit, where he was treated with continuous intravenous infusion of dobutamine (4 µg/min/kg) and furosemide (250 mg/d). Beside these, loading doses of aspirin (300 mg) and clopidogrel (600 mg), and low molecular weight heparin in full dose, were administered as standard therapy for suspicious acute myocardial infarction before planned coronary angiography. Clozapine was discontinued, and haloperidol (30 mg/d) and diazepam (30 mg/d) were induced intramuscularly. The patient refused the recommended coronary angiography and was distrustful to all other proposed diagnostic procedures. After 24 hours, he was hemodynamically stable, and inotropic support was gradually stopped. Heart failure therapy, consisting of eplerenone (25 mg/d) and ivabradine (2 × 5 mg/d), was initiated. Serial echocardiographic examinations over the next 4 days revealed that the left ventricular systolic function completely normalized, and troponin T and NT-proBNP level considerably decreased (228 ng/L and 1190 ng/L, respectively). ECG showing sinus rhythm, rate 82/min with a vertical axis, did not indicate myocardial ischemia. Based on troponin T and NT-proBNP levels, echocardiographic findings, ECG, and clinical restitution, the patient was diagnosed with takotsubo cardiomyopathy. He was then transferred back to the psychiatric department. At that time, clopidogrel was discontinued as the diagnosis of myocardial infarction seemed unlikely. During the next two weeks, echocardiographic exams were unremarkable, and troponin T and NT-proBNP levels were within the reference range (6 ng/L and 69 ng/L, respectively). By the end of week 12, the patient was referred to a chronic psychiatric institution.

DISCUSSION

Our hypothesis was that in our patient clozapine and ECT induced catecholamine activity discordant with beta-blocker effect. Of the 16 reported ECT-induced takotsubo cardiomyopathy cases so far, only one was a young male patient treated with clozapine, but without concomitant beta-blocker therapy (Table 1) (2-16).

Although ECT-related cardiac complications have been occasionally reported, takotsubo cardiomyopathy remains the least understood among them. Takotsubo cardiomyopathy is a transient cardiac syndrome that most often involves left ventricular apical akinesis and mimics acute coronary syndrome, showing ST-segment elevation and...
| Zhu 1992 (6)  | F         | Unknown | 77 | Major depression | Antidepressant | Unknown | Not specified, 1st? | No history of cardiac disease | Unknown |
|-------------|-----------|---------|----|------------------|---------------|---------|---------------------|-------------------------------|---------|
| Eitzman 1994 (7) | F Unknown | 76 | Severe depression | Unknown | Unknown | Unknown | No history of medical treatment | Unknown | |
| Ring 1996 (8) | F Unknown | 41 | Major depressive disorder | Paroxetine 80 mg daily, naltrexone 200 mg daily | Propranolol long-acting 800 mg, propranolol 30 mg four times daily | 1st course; 1st session | Obesity | Unknown | |
| O’Reardon 2008 (16) | F Unknown | 45 | Major depressive disorder | Unknown | Warfarin | 1st course; 3rd session | Deep vein thrombosis with multiple pulmonary emboli, obstructive sleep apnea, hypertension, Loeys-Dietz syndrome | None | |
| Chandra 2009 (12) | F Unknown | 70 | Depression, bipolar disorder | Unknown | Unknown | Unknown | Mitral valve prolapse | Unknown | |
| Go 2009 (9) | F Unknown | 50 | Major depression with suicidal ideation | Quetiapine, venlafaxine, mirtazapine, pregabalin | Ropinirole, metformin, insulin, enalapril, hydroxyzine, fexofenadine, aspirin, furosemide | Unknown course; 3rd session | Type 2 diabetes mellitus, hypertension, obesity, asthma, sleep apnea, degenerative joint disease | Unknown | |
| Go 2009 (9) | F Unknown | 49 | Bipolar disorder, a depressed state with psychotic features | Valproate, fluoxetine, quetiapine, quetiapine | Albuterol, fluticasone/salmeterol | Unknown | Asthma, obesity, dyslipidemia, stress incontinence, impaired glucose tolerance | Unknown | |
| Kent 2009 (13) | F White | 71 | The major depressive episode with psychotic features | Nortriptyline 25 mg daily, quetiapine 200 mg daily, lorazepam 0.5 mg twice daily | Metoprolol extended-release 100 mg twice daily, amlodipine 5 mg twice daily, Nonsteroidal anti-inflammatory medications | 3rd course; 3rd session | Hypertension, costochondritis | Unknown | |
| Satterthwaite 2009 (10) | F White | 72 | Major depression with catatonia | Unknown | Unknown | 1st course; 1st session | Unknown | Unknown | |
| Beach 2010 (1) | F White | 52 | Treatment-resistant depression | Topiramate 200 mg daily, gabapentin 800 mg daily | Not specified, 1st? | Migraine headaches, cholecystectomy | Occasional alcohol use | Unknown | |
| Serby 2010 (5) | F White | 90 | The recurrent major depressive disorder | Duloxetine 60 mg daily | Rantidine 150 mg daily, calcium carbonate 600 mg twice daily, multivitamin once daily | >100 courses | Hypertension (not motensive without medication) | Unknown | |

**TABLE 1.** Case studies about Takotsubo cardiomyopathy after the use of electroconvulsive therapy (ECT) ordered by the year of publishing.
cardiac enzyme levels similar to myocardial infarction (17). However, in takotsubo cardiomyopathy cardiac angiography can confirm no significant coronary artery stenosis. Typical echocardiography reveals left ventricular apical ballooning (17). Several takotsubo cardiomyopathy causes have been proposed, including coronary artery ischemia and microvascular spasm (18). The spasm is induced by a sudden catecholamine increase since patients with takotsubo cardiomyopathy have elevated catecholamine blood concentrations. Takotsubo cardiomyopathy was also strongly associated with mental illnesses (19). Although our patient did not undergo angiography, we find takotsubo cardiomyopathy a more likely diagnosis than ST-elevation myocardial infarction for several reasons. The degree of ECG changes observed in the initial ECG, along with a severely reduced left ventricular ejection fraction, would not likely resolve in 24 hours in a patient with conservatively treated ST elevation myocardial infarction. Furthermore, troponin T peak of <2000 ng/L is rarely observed in cases of anterior myocardial infarction, even when timely reperfusion is performed. The patient could have stable coronary disease due to his significant history of nicotine abuse, which might have temporarily worsened ischemia. However, he never complained of chest pain, either before or after the described event. Moreover, it is unlikely that transient spasm would cause such echocardiographic findings (20). Lastly, deep, symmetric T wave inversion and prolonged QTc interval observed in this case are prominent features of takotsubo cardiomyopathy (17).

Most patients with ECT-induced takotsubo cardiomyopathy were women older than 70 treated for major depression (4-7,10,11,14). Due to hormonal changes, post-menopausal women could be more susceptible to cardiovascular events after a sympathetic response to acute stressors, such as ECT application (18). However, men show a greater autonomic response to stress than pre-menopausal women of the same age (21). Psychosis has been associated with catecholamine dysfunction, and excessive psychological stress with long-term norepinephrine dysfunction (22). Therefore, positive psychotic symptoms in our patient could have led to elevated catecholamine blood concentrations. Grubisha et al (16) reported on a case of takotsubo cardiomyopathy after concomitant ECT and clozapine use, which points to a synergistic effect of ECT and clozapine. Clozapine is a strong antagonist of different subtypes of adrenergic, cholinergic, and histaminergic receptors and systematically elevates epinephrine and norepinephrine levels. Catecholamine hypothesis of ECT-induced takot-

### TABLE 1. CONTINUED. Case studies about Takotsubo cardiomyopathy after the use of electroconvulsive therapy (ECT) ordered by the year of publishing.

| Sex | Ethnicity | Age | Diagnose | Main therapy | Concomitant therapy | Number of ECT applications | Comorbidities | Alcohol/tobacco/illicit drugs use |
|-----|-----------|-----|----------|--------------|---------------------|---------------------------|---------------|----------------------------------|
| F   | Unknown   | 76  | The recurrent major depressive disorder | Mirtazapine, olanzapine | Unknown | 1st course; 11 sessions (1st mECT* session) | Multiple myelomas | Unknown |
| F   | Unknown   | 85  | Depression, anorexia | Unknown | Unknown | Unknown course; 3rd session | Unknown | Unknown |
| M   | Unknown   | 31  | Schizoaffective disorder, pervasive developmental disease | Clozapine 350 mg daily | Zonisamide | 2nd course; 50 treatments | Hypertension, seizure | Unknown |
| F   | White     | 74  | The recurrent major depressive disorder | Venlafaxine, mirtazapine, lithium, aripiprazole | Bisoprolol 2.5 mg/ daily, lisinopril 20 mg/daily | 2nd course; 1st session | Chronic obstructive pulmonary disease, hypertension | None |
| F   | Unknown   | 67  | The recurrent major depressive disorder | Fluvoxamine 300 mg daily, mirtazapine 15 mg daily | Unknown | Unknown (2nd?); 24 sessions (mECT*) | Oropharyngeal cancer | Unknown |

*mECT – maintenance electroconvulsive therapy.
Takotsubo cardiomyopathy is supported by the burst activity of norepinephrine neurons not only due to ECT, but also due to clozapine and nicotine use, as was shown in the locus coeruleus in an animal model (23). How these therapies interact to alter levels of catecholamine remains unclear. Reports on ECT-induced takotsubo cardiomyopathy show that antidepressants alter the neuronal reuptake of plasma catecholamine and facilitate myocardial stunning by increasing local catecholamine levels (Table 1).

Adrenergic blockade before, during, and after ECT minimizes the risk of takotsubo cardiomyopathy recurrence (5). There are a few patients who underwent successful retrials of ECT after having developed takotsubo cardiomyopathy (6). Takotsubo cardiomyopathy treatment includes beta blockers during the period of ventricular recovery (18), and beta blockers have been shown in animal models to improve left ventricular ejection fraction (24). There are three reports on the concomitant use of beta blockers in patients who develop takotsubo cardiomyopathy, similar to our case (5,7,12). Patients may be predisposed to develop takotsubo cardiomyopathy by conditions that raise baseline catecholamine level (17,19). Both caffeine and nicotine elevate catecholamine blood levels (25), and our patient’s caffeine and nicotine use could have precipitated a cardiovascular accident. In this case, simultaneous effects of clozapine, caffeine, nicotine, and ECT, along with male sex, seem to have overpowered the protective effect of beta blockers on takotsubo cardiomyopathy development.

In conclusion, our case shows that takotsubo cardiomyopathy can occur as a rare complication of ECT in a male psychotic patient, despite the concomitant beta-blockade treatment. Clinical understanding of rare cardiac ECT complications could improve early recognition of patients at risk for takotsubo cardiomyopathy and ensure safe ECT protocols.

Funding None.

Ethical approval received from the University Hospital Centre Zagreb for ECT application. The patient also signed informed consent for medical data publication.

Declaration of authorship SM conceived and designed the study; all authors acquired the data; analyzed and interpreted the data; drafted the manuscript; critically revised the manuscript for important intellectual content; gave approval of the version to be submitted, agree to be accountable for all aspects of the work.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References
1 Mihaljević-Peleš A, Bajs Janović M, Stručić A, Šagud M, Skočić Hanžek M, Živković M, et al. Electroconvulsive therapy - general considerations and experience in Croatia. Psychiat Danub. 2018;30:188-91. Medline:29864758
2 Beach SR, Wichman CL, Canterbury RJ. Takotsubo cardiomyopathy after electroconvulsive therapy. Psychosomatics. 2010;51:432-6. Medline:20833943 doi:10.1016/S0033-3182(10)70726-X
3 Grubisha M, Gopalan P, Azzam PN. Takotsubo cardiomyopathy in a young man after maintenance electroconvulsive therapy and clozapine initiation. J ECT. 2014;30:e40-1. Medline:24625715 doi:10.1097/YCT.0000000000000111
4 De Wolf MM, Bijvank EG. Takotsubo-cardiomyatie als complicatie van elektroconvulsietherapie [Takotsubo cardiomyopathy as complication of electroconvulsive therapy]. Tijdschr Psychiat. 2015;57:361-6. Medline:26028017
5 Serby MJ, Lantz M, Chabus BL, Bernay LJ. Takotsubo cardiomyopathy and electroconvulsive treatments: a case study and review. Int J Psychiatry Med. 2010;40:93-6. Medline:20565047 doi:10.2190/PM.40.1.g
6 Zhu WX, Olsen DE, Karpn BL, Tajik AJ. Myocardial stunning after electroconvulsive therapy. Ann Intern Med. 1992;117:914-5. Medline:1443953 doi:10.3236/0003-4819-117-11-914
7 Eitzman DT, Bach DS, Rubenfire M. Management of myocardial stunning associated with electroconvulsive therapy guided by hyperventilation echocardiography. Am Heart J. 1994;127:928-9. Medline:8154433 doi:10.1016/0002-8703(94)90563-0
8 Ring BS, Parnass SM, Shulman RB, Phelan J, Khan SA. Cardiogenic shock after electroconvulsive therapy. Anesthesiology. 1996;84:1511-3. Medline:8669696 doi:10.1097/00000542-199606000-00031
9 Go O, Mukherjee R, Bhatta L, Carhart R, Villarreal D. Myocardial stunning after electroconvulsive therapy in patients with an apparently normal heart. J ECT. 2009;25:117-20. Medline:19225404 doi:10.1097/YCT.0b013e318197e1cbf
10 Satterthwaite TD, Cristancho MA, Alici Y, Weiss D, O’Reardon JP. Electroconvulsive therapy in a 72-year-old woman with a history of Takotsubo cardiomyopathy: a case report and review of the literature. Brain Stimul. 2009;2:238-40. Medline:20633423 doi:10.1016/j.brs.2009.02.003
11 Binhas M, Liger C, Sedaghati A, Gilton A, Dhoune-G. Quand reprendre l’électroconvulsivothérapie après une cardiomyopathie de Takotsubo induite par sismothérapie? [When reitral of ECT is possible after ECT-induced Takotsubo cardiomyopathy?]. Ann Fr Anesth Reanim. 2013;32:723-4. Medline:23993154 doi:10.1016/j.anfar.2013.07.810
12 Chandra PA, Golduber G, Chuprun D, Chandra AB. Tako-tsubo cardiomyopathy following electroconvulsive therapy. J Cardiovasc Med (Hagerstown). 2009;10:333-5. Medline:19430344 doi:10.2459/JCM.0b013e328324eb0d
13 Kent LK, Weston CA, Hayer EJ, Sherman W, Prudic J. Successful retrial of ECT two months after ECT-induced takotsubo cardiomyopathy. Am J Psychiatry. 2009;166:857-62. Medline:19651751 doi:10.1176/appi.ajp.2008.08081278

14 Celano CM, Torri A, Seiner S. Takotsubo cardiomyopathy after electroconvulsive therapy: a case report and review. J ECT. 2011;27:221-3. Medline:21673587 doi:10.1097/YCT.0b013e31821537c0

15 Narayanan A, Russell MD, Sundararaman S, Shankar KK, Artman B. Takotsubo cardiomyopathy following electroconvulsive therapy: An increasingly recognised phenomenon. BMJ Case Rep. 2014;2014:bcr2014206816. Medline:25425252 doi:10.1136/bcr-2014-206816

16 O’Reardon JP, Lott JP, Akhtar UW, Cristancho P, Weiss D, Jones N. Acute coronary syndrome (Takotsubo cardiomyopathy) following electroconvulsive therapy in the absence of significant coronary artery disease: case report and review of the literature. J ECT. 2008;24:277-80. Medline:18955900 doi:10.1097/YCT.0b013e31815f4a4b

17 Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:929-38. Medline:26332547 doi:10.1056/NEJMoa1406761

18 Wittstein IS. Stress cardiomyopathy: a syndrome of catecholamine-mediated myocardial stunning? Cell Mol Neurobiol. 2012;32:847-57. Medline:22297544 doi:10.1007/s10571-012-9804-8

19 Nayeri A, Rafia-Yuan E, Krishnan S, Ziaeean B, Cadeiras M, McPherson JA, et al. Psychiatric illness in takotsubo (stress) cardiomyopathy: a review. Psychosomatics. 2018;59:220-6. Medline:29544664 doi:10.1016/j.psym.2018.01.011

20 Medeiros K, O’Connor MJ, Baicu CF, Fitzgibbons TP, Shaw P, Tighe DA, et al. Systolic and diastolic mechanics in stress cardiomyopathy. Circulation. 2014;129:1659-67. Medline:24503950 doi:10.1161/CIRCULATIONAHA.113.002781

21 Kajantie E, Phillips DIW, Kuo TB, Yin C-S, Chen HI, Kirschbaum C, et al. The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology. 2006;31:151-78. Medline:16139959 doi:10.1016/j.psyneuen.2005.07.002

22 Yamamoto K, Shinba T, Yoshi M. Psychiatric symptoms of noradrenergic dysfunction: a pathophysiological view. Psychiatry Clin Neurosci. 2014;68:1-20. Medline:24372896 doi:10.1111/pcn.12126

23 Tsen P, El Mansari M, Blier P. Effects of repeated electroconvulsive shocks on catecholamine systems: Electrophysiological studies in the rat brain. Synapse. 2013;67:716-27. Medline:23740835 doi:10.1002/syn.21685

24 Izumi Y, Okatani H, Shiota M, Nakao T, Ise R, Kito G, et al. Effects of metoprolol on epinephrine-induced takotsubo-like left ventricular dysfunction in non-human primates. Hypertens Res. 2009;32:339-46. Medline:19300450 doi:10.1038/hr.2009.28

25 Tully PJ, Harrison NJ, Cheung P, Cosh S. Anxiety and cardiovascular disease risk: a review. Curr Cardiol Rep. 2016;18:120. Medline:27796859 doi:10.1007/s11886-016-0800-3